Tivic Health Systems (TIVC)
Develops TLR5 immunotherapies and biomanufacturing services for radiation and oncology uses.
Something off on this page? Send us feedback.
Tivic Health Systems is a Nasdaq-listed healthcare company that shifted from consumer bioelectronic devices to clinical-stage immunotherapy. Its lead candidate is Entolimod, a TLR5 agonist for acute radiation syndrome, and its Velocity Bioworks subsidiary adds biomanufacturing and CDMO services.
Tivic Health Systems, Inc. is a clinical-stage biopharmaceutical company that trades on the Nasdaq Capital Market under TIVC. The company repositioned in 2025 from a consumer bioelectronic medical-device business into an immunotherapy-focused platform built around Toll-like Receptor 5 biology. Its lead program, Entolimod, is being developed for acute radiation syndrome and related radiation or oncology supportive-care uses; filings describe it as pre-BLA under the FDA Animal Rule and note Fast Track and Orphan Drug designations.
Tivic also holds rights to Entolasta, a next-generation TLR5 agonist. Its Velocity Bioworks subsidiary in San Antonio provides internal manufacturing support and offers CDMO services to external biotech customers. The company discontinued ClearUP operations and suspended non-core neuromodulation work, so execution now depends on clinical, regulatory, government funding, manufacturing, and CDMO customer progress.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.1M · Total debt $10.0M · Total assets $32.5M · Shareholders' equity $11.9M
- Revenue
- $0
- Operating income
- −$6.4M
- Net income
- −$7.1M
No dividends on record.
| Institutions | ≥ 1.79% | 398.1K shares | |
|---|---|---|---|
| 13 holders · as of Jun 30, 2026 | |||
| Insiders | 0.32% | 71.0K shares | |
| 5 holders · as of Apr 20, 2026 | |||
| Other | ≤ 97.89% | 21.72M shares | |
| remainder | |||
22.19M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (22.19M in the company's Sep 22, 2026 report, 1.08M elsewhere); stakes use the report.
Institutional filings for VBIO (100% of the company) are not on file here, so the institutional figure is a floor.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Murchinson Ltd.Institution | 0.52% | 115,000 | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 0.33% | 74,145 | as of Jun 30, 2026 |
Sanctuary Advisors, LLCInstitution | 0.28% | 61,205 | as of Jun 30, 2026 |
Marex Group PLCInstitution | 0.24% | 54,287 | as of Jun 30, 2026 |
Virtu Financial LLCInstitution | 0.18% | 39,225 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 15, 2026 | Sheryle Bolton | director | +10,000 | $1.04 |
| Apr 1, 2026 | Christina Rizopoulos Valauri | director | +19,000 | $0.9478 |
Not reported.